Free Trial
NASDAQ:FBIO

Fortress Biotech (FBIO) Stock Price, News & Analysis

Fortress Biotech logo
$1.99 +0.06 (+3.11%)
Closing price 04:00 PM Eastern
Extended Trading
$1.98 -0.01 (-0.75%)
As of 07:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Fortress Biotech Stock (NASDAQ:FBIO)

Key Stats

Today's Range
$1.91
$2.03
50-Day Range
$1.65
$2.13
52-Week Range
$1.33
$2.89
Volume
228,309 shs
Average Volume
413,427 shs
Market Capitalization
$58.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00
Consensus Rating
Buy

Company Overview

Fortress Biotech Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
43rd Percentile Overall Score

FBIO MarketRank™: 

Fortress Biotech scored higher than 43% of companies evaluated by MarketBeat, and ranked 624th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Fortress Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Fortress Biotech has received no research coverage in the past 90 days.

  • Read more about Fortress Biotech's stock forecast and price target.
  • Earnings Growth

    Earnings for Fortress Biotech are expected to grow in the coming year, from ($3.28) to ($1.13) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Fortress Biotech is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Fortress Biotech is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Fortress Biotech's valuation and earnings.
  • Percentage of Shares Shorted

    15.57% of the float of Fortress Biotech has been sold short.
  • Short Interest Ratio / Days to Cover

    Fortress Biotech has a short interest ratio ("days to cover") of 15.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Fortress Biotech has recently decreased by 2.08%, indicating that investor sentiment is improving.
  • Dividend Yield

    Fortress Biotech does not currently pay a dividend.

  • Dividend Growth

    Fortress Biotech does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    15.57% of the float of Fortress Biotech has been sold short.
  • Short Interest Ratio / Days to Cover

    Fortress Biotech has a short interest ratio ("days to cover") of 15.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Fortress Biotech has recently decreased by 2.08%, indicating that investor sentiment is improving.
  • Search Interest

    6 people have searched for FBIO on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Fortress Biotech insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    27.90% of the stock of Fortress Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    96.51% of the stock of Fortress Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Fortress Biotech's insider trading history.
Receive FBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fortress Biotech and its competitors with MarketBeat's FREE daily newsletter.

FBIO Stock News Headlines

FBIO Fortress Biotech, Inc. - Seeking Alpha
Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
See More Headlines

FBIO Stock Analysis - Frequently Asked Questions

Fortress Biotech's stock was trading at $2.03 on January 1st, 2025. Since then, FBIO shares have decreased by 2.0% and is now trading at $1.99.

Fortress Biotech, Inc. (NASDAQ:FBIO) released its earnings results on Monday, March, 31st. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, topping analysts' consensus estimates of ($0.79) by $0.53. The biopharmaceutical company had revenue of $15.12 million for the quarter, compared to analyst estimates of $16.30 million. Fortress Biotech had a negative trailing twelve-month return on equity of 4,712.53% and a negative net margin of 71.24%.
Read the conference call transcript
.

Fortress Biotech shares reverse split before market open on Tuesday, October 10th 2023.The 1-15 reverse split was announced on Monday, October 9th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Shares of FBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Fortress Biotech investors own include Plug Power (PLUG), FuelCell Energy (FCEL), Workhorse Group (WKHS), KALA BIO (KALA), Ovid Therapeutics (OVID), Lipocine (LPCN) and Comtech Telecommunications (CMTL).

Company Calendar

Last Earnings
3/31/2025
Today
7/09/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:FBIO
CIK
1429260
Employees
170
Year Founded
N/A

Price Target and Rating

High Price Target
$26.00
Low Price Target
$16.00
Potential Upside/Downside
+955.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$46 million
Pretax Margin
-183.81%

Debt

Sales & Book Value

Annual Sales
$57.67 million
Price / Cash Flow
N/A
Book Value
($0.06) per share
Price / Book
-33.17

Miscellaneous

Free Float
21,320,000
Market Cap
$58.84 million
Optionable
Optionable
Beta
1.75

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:FBIO) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners